NasdaqGS:ANABBiotechs
AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth?
AnaptysBio (ANAB), a clinical stage biotech focused on immunology therapeutics, continues to attract attention as investors weigh its recent share performance, clinical pipeline progress and current valuation at a market cap of about US$1.73b.
See our latest analysis for AnaptysBio.
At a share price of US$58.48, AnaptysBio has seen its short term share price return slip over the past quarter. Its year to date share price return of 30.10% and very large 1 year total shareholder return suggest...